DIAGNOSIS OF CARDIAC ISCHEMIA WITH UNBOUND FFA

描述：（申请人摘要）本提案的长期目标是 建立一种简单的基于血液的检测方法，用于心肌梗死的早期诊断。 缺血缺血性心脏病是美国的主要死因 States.目前的诊断方法要么不可靠，要么复杂， 贵了心脏标志物检测可靠地检测坏死，但不能检测缺血， se.与此相反，我们提出的诊断方法，测量血清 非结合FFA（FFAu），涉及一种简单、廉价、几乎瞬时的， 和容易获得的测量，具有很高的潜力，揭示 缺血性事件。在拟定的I期研究中，我们将确定血浆 用我们的ADIFAB荧光方法测量的FFAu水平，提供了早期的 大鼠心肌缺血的指标。如果，正如我们从初步的预期 研究表明，血浆中的FFAu水平在几分钟内就会上升到非常高的水平， 在缺血性损伤之后，那么我们应该能够使用大鼠模型， 帮助定义该检测试剂盒的特征，为II期临床试验做准备 在人类患者中进行试验。 拟定商业应用： 如果成功，这项研究将表明，游离脂肪酸（FFAu） 提供最早和最灵敏的基于血液分析的心肌 缺血 如果得到随后的第二阶段和第三阶段试验的支持，我们预计， 与一个小的，便宜的单一用途的荧光计，这种测定将 用于提供心肌缺血的最早指征。 该测定基于 我们的专利方法是唯一报道的测量FFAu的方法， 确保了可观的商业应用。

DESCRIPTION: (Applicant's abstract) The long term goal of this proposal is to develop a simple blood-based assay for the early diagnosis of myocardial ischemia. lschemic heart disease is the major cause of death in the United States. Current methods of diagnosis are either unreliable or complex and expensive. Cardiac marker assays reliably detect necrosis but not ischemia per se. In contrast, the diagnostic method we propose, the measurement of serum unbound FFA (FFAu), involves a simple, inexpensive, virtually instantaneous, and readily accessible measurement that has high potential for revealing the ischemic event. In the proposed Phase I studies we will determine if plasma FFAu levels, measured with our ADIFAB fluorescence method, provide an early indicator of cardiac ischemia in the rat. If, as we expect from preliminary studies, plasma levels of FFAu rise to very high levels within minutes following the ischemic insult, then we should be able to use the rat model to help define the characteristics of this assay in preparation for a Phase II trial in human patients. PROPOSED COMMERCIAL APPLICATION: If successful this research would demonstrate that unbound free fatty acids (FFAu) provide the earliest and most sensitive blood-assay based measure of myocardial ischemia. If supported by subsequent phase II and III trials, we would expect, in conjunction with a small, inexpensive single purpose fluorometer, that this assay would be used to provide the earliest indication of myocardial ischemia. This assay is based on our patented method which is the only reported method for measuring FFAu, thereby ensuring considerable commercial application.